EPB158 Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naïve participants receiving dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING StudyE-posterART in highly treatment-experienced persons
EPB157 Comparison of virologic suppression rates among first- and second-line antiretroviral therapy patients at an urban clinic in Zimbabwe: a cohort studyE-posterART in highly treatment-experienced persons
EPB156 How clinical trials of combination antiretroviral therapy for adults with HIV capture health-related quality of life with patient-reported measures: a systematic reviewE-posterART in highly treatment-experienced persons
EPB155 The presence of minority HIV Drug resistance variants in the protease and Gag regions confers poor response to therapy among subtype A and D patientsE-posterART in highly treatment-experienced persons
EPB154 Doravirine associated resistance mutations in antiretroviral therapy naïve and experienced HIV-1C infected people in BotswanaE-posterART in highly treatment-experienced persons
EPB153 Starting antiretroviral therapy (ART) at the first HIV-specialist appointment with or without baseline laboratory data with BIC/FTC/TAF (The BIFAST study)E-posterART in acute, first- and second-line therapies
EPB152 Country of birth influences INSTI prescription in treatment-naive patients living with HIV in FranceE-posterART in acute, first- and second-line therapies
EPB151 A pilot study of the impact of a rapid ART initiation in advanced HIV diseaseE-posterART in acute, first- and second-line therapies
EPB150 Long-term integrated analysis of B/F/TAF in treatment-naïve adults with HIV through five years of follow-upE-posterART in acute, first- and second-line therapies
EPB149 Higher CD4/CD8 ratio recovery observed among people living with HIV started with integrase strand transfer inhibitorsE-posterART in acute, first- and second-line therapies
2241 - 2250 of 2485 items